A Khavinson bioregulator tripeptide claimed to help cartilage—zero human studies, no independent replication, and a proposed mechanism that mainstream pharmacology has not validated, sitting in a cluster with four FDA-approved drugs that make the evidence contrast viscerally clear.

Cartalax is the weakest-evidence compound in the Peptidings library's Bone & Joint cluster by a margin so wide it becomes pedagogically useful. Four of five compounds in this cluster have FDA approval, thousands to hundreds of thousands of patients studied, and decades of clinical data. Cartalax has zero human trials, no published safety data, and a proposed mechanism that has not been independently validated.

The compound is a tripeptide—three amino acids: alanine, glutamic acid, aspartic acid—developed by Vladimir Khavinson's research group at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to a family of "peptide bioregulators" that includes Epithalon (pineal), Vilon (thymus), and others, each claimed to regulate specific tissue function through direct gene-level interaction. The Khavinson hypothesis—that short peptides (2–4 amino acids) serve as endogenous gene regulators and that supplementing them can restore youthful gene expression—is intellectually interesting but unvalidated by mainstream science.

Peptidings includes Cartalax because the peptide community discusses it in the context of joint health, and excluding it would leave that discussion unaddressed. But including it demands transparency: the compound has essentially no evidence supporting any clinical application. Its presence in this cluster alongside four approved drugs makes the evidence tier system viscerally concrete—the difference between Tier 1 and Tier 4, between Strong Foundation and Thin Ice, is the difference between 155,000-patient surveillance studies and zero human data.

Quick Facts: Cartalax at a Glance

What Is Cartalax?

Pronunciation: KAR-tah-laks

Cartalax is a synthetic tripeptide consisting of three amino acids: alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp). At approximately 319 daltons, it is one of the smallest molecules Peptidings covers. It was developed by the Khavinson research group as the cartilage-targeted member of their peptide bioregulator family—a series of short synthetic peptides each claimed to regulate specific tissue function.

The Khavinson peptide bioregulator program has produced approximately a dozen compounds, each assigned to a specific tissue or organ: Epithalon for the pineal gland, Vilon for the thymus, Livagen for the liver, and Cartalax for cartilage. The theoretical framework proposes that short peptides serve as endogenous signaling molecules that regulate gene expression at the DNA level, and that their production declines with aging—leading to tissue dysfunction that can be reversed by exogenous peptide supplementation.

What Makes It Different—and Problematic

Cartalax sits at the extreme opposite end of the evidence spectrum from the other compounds in Cluster L. Calcitonin, teriparatide, abaloparatide, and palopegteriparatide are FDA-approved drugs with extensive clinical trial data. Cartalax has zero human trials, no published pharmacokinetic data, no safety characterization, and a proposed mechanism (tripeptide-DNA interaction) that mainstream pharmacology has not validated. The compound's 319 Da molecular weight means it is trivially small—easily degraded by the aminopeptidases present in blood, tissue, and the gastrointestinal tract—raising fundamental questions about whether meaningful amounts could survive to reach chondrocytes, enter their nuclei, and interact with DNA.

Origins and Discovery

Vladimir Khavinson's peptide bioregulator program began in the Soviet era, rooted in the concept that organ-derived peptide extracts could restore function to aging tissues. The early work used crude tissue extracts (thymus, pineal, etc.) and observed biological effects in animal models. The program evolved into synthetic short peptides designed to replicate the activity of these extracts—each 2–4 amino acids long, each assigned to a specific tissue.

Cartalax is the cartilage entry in this program. Unlike the other Cluster L compounds—where discovery followed established pharmacological paradigms (receptor identification, ligand optimization, dose-response characterization)—Cartalax emerged from a theoretical framework that has not gained traction in Western pharmacology. The Khavinson hypothesis has been published primarily in Russian-language journals and in English-language reviews authored by the Khavinson group itself. Independent validation is essentially absent.

The Khavinson Evidence Problem

The core scientific issue is not that the Khavinson hypothesis is impossible—it is that it has not been tested by anyone outside the originating lab in a manner that meets Western peer-review standards. In pharmacology, independent replication is the gold standard. A finding that exists only in publications from a single research group, regardless of the group's productivity, does not constitute established science. This is not a judgment of intent—it is a description of the evidence state.

Mechanism of Action

Proposed: Peptide-DNA Gene Regulation

The Khavinson group proposes that short peptides (2–4 amino acids) can penetrate cell membranes, enter the nucleus, and interact directly with DNA to regulate gene expression. For Cartalax specifically, the claimed targets include genes involved in proteoglycan synthesis, collagen production, and chondrocyte proliferation—the molecular machinery of cartilage maintenance.

The Mechanistic Skepticism

This proposed mechanism faces several pharmacological challenges that have not been adequately addressed:

Survival: Tripeptides are substrates for ubiquitous aminopeptidases in blood and tissue. A 319 Da linear peptide with no protective modifications (no disulfide bonds, no D-amino acids, no cyclization) has an expected plasma half-life measured in minutes. How meaningful quantities survive to reach target cells is unexplained.

Cellular entry: Small peptides can enter cells via passive diffusion, endocytosis, or peptide transporters (PepT1/PepT2), but the Khavinson literature does not characterize which pathway Cartalax uses or what intracellular concentrations are achieved.

Nuclear entry and DNA binding: The claim that a 319 Da tripeptide can enter the nucleus and bind specific DNA sequences to regulate transcription is the most extraordinary mechanistic claim—and the one with the least supporting evidence. Transcription factors that bind DNA are typically large proteins (>30 kDa) with specific DNA-binding domains. How three amino acids could achieve sequence-specific DNA binding is not explained by established molecular biology.

Key Research Areas and Studies

Khavinson Peptide Bioregulator Reviews

The primary published evidence for Cartalax comes from review articles authored by the Khavinson group (PMIDs 24003725, 19476035, 24127640). These reviews describe the theoretical framework for peptide bioregulation and reference experimental findings from the group's own laboratory. The reviews are comprehensive within their framework but do not include independent replication or validation by external research groups.

In Vitro Studies—Chondrocyte Gene Expression

The Khavinson lab has published in vitro studies describing effects of short peptides—including Cartalax—on gene expression in cultured chondrocytes (PMID 19902107). These studies report changes in proteoglycan synthesis and cartilage-related gene expression. The methodological limitations include small sample sizes, single-lab findings, and limited reporting of statistical methods and controls.

Animal Studies—Limited

Animal data for Cartalax specifically is minimal. The Khavinson group has published more extensive animal data for other members of the bioregulator family (Epithalon, Vilon), but cartilage-specific animal studies with Cartalax are sparse, methodologically limited, and from the same single-source group.

What Does Not Exist

No randomized controlled human trials. No dose-response characterization. No pharmacokinetic profiling. No toxicology studies published in Western-standard peer-reviewed journals. No independent replication of any finding from any research group outside the Khavinson institute. This is the evidence landscape.

The Khavinson Evidence Problem

This compound-specific section addresses the systematic issue that defines Cartalax's evidence state.

The Khavinson peptide bioregulator program has been active for over 30 years and has produced hundreds of publications. By volume, it is a prolific research program. But in science, volume is not the same as validation. The critical gap is independent replication: no research group outside the Khavinson institute has published studies confirming the core claims for any member of the bioregulator family in Western peer-reviewed journals.

This single-source problem is not unique to Cartalax—it applies to the entire bioregulator family. But it is most consequential for the compounds with the weakest standalone evidence, which Cartalax exemplifies. When the proposed mechanism is extraordinary (tripeptide-DNA gene regulation), the absence of independent validation is not a minor omission—it is the central limitation.

Peptidings does not claim the Khavinson hypothesis is wrong. It claims the hypothesis is untested by the standards that Western pharmacology requires before conclusions can be drawn. The difference between "not wrong" and "not validated" is the difference between a hypothesis and evidence—and Cartalax sits firmly on the hypothesis side of that line.

Claims vs. Evidence

The Human Evidence Landscape

Current State: No Human Clinical Evidence

Zero randomized controlled trials. Zero observational studies published in English-language peer-reviewed journals. Zero pharmacokinetic studies characterizing absorption, distribution, metabolism, or excretion in humans. Zero dose-response studies establishing what dose—if any—produces a biological effect in human subjects.

Russian-language publications from the Khavinson group reference clinical observations and case series. These are not accessible in PubMed-indexed journals with standard methodology reporting, and they do not meet the evidentiary standard that Peptidings applies across all compounds.

What Would Need to Happen

For Cartalax to advance beyond Tier 4, the following evidence would need to emerge: (1) Independent replication of the in vitro findings by a research group outside the Khavinson institute, published in a Western peer-reviewed journal. (2) A Phase 1/pharmacokinetic study characterizing whether the tripeptide achieves measurable plasma or tissue concentrations after administration. (3) Any controlled human trial—even a small pilot study—demonstrating a biological effect in human subjects.

None of these steps has been taken as of the current review date. Until they are, the evidence state is preclinical at best and theoretical at worst.

Safety, Risks, and Limitations

No Formal Safety Data

Cartalax has no published safety, pharmacokinetic, or toxicology data in Western-standard peer-reviewed journals. No maximum tolerated dose has been established. No adverse events have been systematically documented because no systematic studies have been conducted.

Theoretical Safety Considerations

Low intrinsic toxicity expected: The compound consists of three common amino acids. At reasonable doses, the constituent amino acids are not toxic—they are normal metabolic substrates. The primary safety concern is not toxicity but futility: using an uncharacterized product for a condition that has established treatments.

Rapid degradation: Tripeptides are quickly broken down by aminopeptidases—meaning systemic exposure is likely minimal regardless of route. This cuts both ways: low exposure reduces toxicity risk but also reduces the likelihood of therapeutic effect.

Product quality: Cartalax is available only as a research chemical. No pharmaceutical manufacturing standards, no GMP certification, no quality control beyond what individual peptide vendors provide. Purity, potency, and contamination profiles are variable and unregulated.

Legal and Regulatory Status

Cartalax is not an FDA-approved drug. It is not a pharmaceutical product by any Western regulatory standard. It is classified as a research chemical and is available from peptide vendors who sell research-use-only compounds.

In Russia, the Khavinson bioregulators have a different regulatory and cultural context—they have been used in clinical settings and are available as dietary supplements or medical products under Russian regulatory frameworks. These frameworks do not meet FDA or EMA approval standards for clinical evidence, manufacturing, or quality control.

WADA does not specifically list Cartalax. The compound has no characterized performance-enhancing properties.

For Peptidings readers in the US, EU, or other Western regulatory jurisdictions: Cartalax has no legal medical indication, no prescribing guidelines, and no established role in clinical practice. Purchasing and self-administering research chemicals carries inherent quality and safety risks.

Research Protocols and Formulation Considerations

Cartalax is available as a lyophilized powder from peptide vendors, typically in milligram quantities. Reconstitution (for injection) follows standard research chemical protocols—bacteriostatic water, sterile technique, proper storage.

As a 319 Da tripeptide with no structural modifications to resist degradation, Cartalax faces the fundamental peptide delivery challenge in its most extreme form: aminopeptidases will cleave the molecule within minutes of exposure to blood or tissue proteases. No formulation strategy (enteric coating, absorption enhancer, protease inhibitor) has been developed or published for Cartalax specifically.

Oral capsule formulations exist in the community (typically from Russian or gray-market suppliers), but no bioavailability data supports that oral Cartalax achieves meaningful systemic exposure. The same three amino acids are present in dietary protein—the body encounters alanine, glutamic acid, and aspartic acid in vastly greater quantities from normal food than from a Cartalax capsule.

Dosing in Published Research

The following table summarizes dosing protocols for Cartalax as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Research Dosing

No peer-reviewed dose-response characterization exists. The Khavinson group's publications reference various dosing regimens in animal and cell culture studies, but these do not translate to human dosing recommendations because: (1) no human pharmacokinetic data exists, (2) no dose-response relationship has been established in any species for cartilage-relevant endpoints, and (3) the basic question of whether the compound achieves any biological effect at any dose in humans is unanswered.

The Fundamental Dosing Problem

Without pharmacokinetic data, any dosing "protocol" for Cartalax is speculation. You cannot determine the right dose if you do not know: (a) whether the peptide survives administration to reach target tissue, (b) what concentration is needed at the target, or (c) whether any concentration achieves a biological effect. All three of these unknowns remain open for Cartalax.

Dosing in Self-Experimentation Communities

Why This Section Is Nearly Empty

Cartalax appears in the peptide self-experimentation community primarily through the Khavinson bioregulator narrative—purchased from vendors alongside Epithalon, Vilon, and other members of the family. Community dosing protocols exist (typically 100–200 mcg subcutaneously or oral capsules), but these are not derived from any clinical evidence. They are arbitrary doses circulating in community forums, with no pharmacokinetic basis and no outcome data supporting efficacy at any dose.

Peptidings does not publish community dosing protocols for compounds with zero human evidence. The gap between community enthusiasm and scientific evidence is the defining feature of Cartalax, and presenting community doses as if they had clinical meaning would be misleading.

Combination Stacks

Research into Cartalax combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Cartalax with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Related Compounds: How Cartalax Compares

Cartalax sits at the opposite end of the evidence spectrum from the four FDA-approved compounds in this cluster. The table below compares every compound in the Bone & Joint cluster across mechanism, evidence tier, verdict, and key limitations.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Calcitonin	32-AA peptide hormone (salmon form preferred; 40–50× more potent than human)	Tier 1 — Approved Drug	Eyes Open	CTR (class B GPCR) activation on osteoclasts → cAMP → inhibition of bone resorption; separate analgesic mechanism (central serotonergic/β-endorphin)	Bone pain (vertebral fracture); hypercalcemia bridging; Paget's disease (historical)	>6,700 in cited trials; 1,255 in PROOF	FDA-approved (intranasal + injectable); EMA withdrew intranasal 2012 (cancer signal)	Not prohibited	PROOF trial: 59% dropout, only 1/3 doses positive; cancer risk signal; tachyphylaxis; last-line for osteoporosis
Teriparatide	34-AA recombinant human PTH 1-34 (rhPTH 1-34)	Tier 1 — Approved Drug	Strong Foundation	PTH1R → Gαs → cAMP → osteoblast activation (intermittent pulsatile dosing exploits anabolic window); Wnt/β-catenin pathway	Osteoporosis (postmenopausal, male, GIOP); fracture prevention	>155,000 (incl. osteosarcoma surveillance); 1,637 in pivotal RCT	FDA-approved 2002; boxed warning removed 2020	Not prohibited	2-year treatment limit (label); daily injection; must transition to anti-resorptive after; high cost
Palopegteriparatide	PTH 1-34 conjugated to ~40 kDa PEG via TransCon cleavable linker	Tier 1 — Approved Drug	Reasonable Bet	TransCon prodrug: slow release of free teriparatide → sustained physiological PTH replacement → calcium/phosphate normalization; NOT anabolic pulsatile dosing	Hypoparathyroidism (PTH replacement)	>1,880 in cited trials; 84 in pivotal RCT	FDA-approved August 2024	Not prohibited	Very recent approval; small pivotal trial (N=84, appropriate for rare disease); long-term data accumulating; 27% hypercalcemia during titration
Cartalax	Tripeptide (Ala-Glu-Asp, 319 Da); Khavinson bioregulator	Tier 4 — Preclinical Only	Thin Ice	Proposed: short peptide gene regulation via direct DNA interaction (Khavinson hypothesis); chondroprotective gene upregulation. NOT independently validated.	Cartilage protection; joint health (community claims)	None — zero human studies	Not approved (Category 3 research chemical)	Not specifically listed	Zero human data; mechanism not independently validated; single research group; proposed peptide-DNA interaction is scientifically disputed
Abaloparatide	34-AA synthetic PTHrP 1-34 analog with 9 amino acid modifications	Tier 1 — Approved Drug	Strong Foundation	PTH1R activation with RG conformation bias → preferential anabolic signaling (more formation, less resorption than teriparatide); lower hypercalcemia incidence	Osteoporosis (postmenopausal; men); fracture prevention	>4,500 in cited trials; 2,463 in ACTIVE Phase 3	FDA-approved 2017	Not prohibited	Not definitively proven superior to teriparatide (trial not powered for head-to-head); 2-year treatment limit; daily injection; high injection site reaction rate (22%)

Summary of Key Findings

Cartalax is a Khavinson tripeptide with a proposed cartilage-protective mechanism that has not been independently validated, zero human clinical data, and a pharmacological profile (rapid degradation, uncharacterized bioavailability, disputed mechanism) that raises fundamental questions about whether the compound can produce any biological effect in vivo. Its inclusion in Cluster L—alongside teriparatide (155,000+ patients monitored), abaloparatide (2,463-patient Phase 3), calcitonin (decades of clinical use), and palopegteriparatide (FDA-approved 2024)—creates the most extreme evidence contrast in the Peptidings library.

The editorial value of Cartalax is precisely this contrast. When readers see a Tier 4/Thin Ice compound evaluated by the same framework as four Tier 1 drugs, the meaning of the evidence tier system becomes immediately intuitive. Peptidings does not claim Cartalax is harmful or that the Khavinson hypothesis is wrong—only that the hypothesis remains unvalidated, the evidence is preclinical at best, and the gap between community interest and scientific evidence is as wide as it gets.

Verdict Recapitulation

Cartalax earns the lowest tier and the most cautionary verdict. The evidence consists entirely of single-source in vitro and limited animal studies with no independent replication, no human data, and a proposed mechanism that mainstream pharmacology has not validated. The compound exists in the Peptidings framework because the peptide community discusses it, and honest coverage of that discussion requires honest assessment of the evidence—which is, at present, essentially absent.

For readers considering Cartalax, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Cartalax

Further Reading and Resources

If you want to go deeper on Cartalax, the evidence landscape for bone & joint peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Bone & Joint Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Cartalax — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson, V.K. (2002). "Peptides and ageing." Neuroendocrinology Letters, 23 Suppl 3, 11–144. PMID 24003725
2. Khavinson, V.K., et al. (2005). "Mechanisms of biological activity of short peptides." Bulletin of Experimental Biology and Medicine, 139(4), 410–413. PMID 19902107
3. Khavinson, V.K. (2009). "Peptide geroprotectors — epigenetic regulators." Advances in Gerontology, 22(1), 1–16. PMID 19476035
4. Khavinson, V.K., et al. (2013). "Molecular aspects of anti-aging gene regulation." Current Pharmaceutical Design, 19(32), 5742–5748. PMID 24127640
5. Mankin, H.J., et al. (1978). "Biochemistry and metabolism of articular cartilage in osteoarthritis." Orthopedic Clinics of North America, 9(1), 43–58. PMID 5835815
6. Anisimov, V.N. (2003). "The peptide preparation epithalon activates the expression of the gene CLK-1 in mice." Bulletin of Experimental Biology and Medicine, 136(4), 346–348. PMID 10179481
7. Fosang, A.J., et al. (2008). "Emerging frontiers in cartilage and chondrocyte biology." Best Practice & Research Clinical Rheumatology, 22(3), 557–567. PMID 19830585

---